Long-Term Bets, Near-Term Miss — Credibility on the Line

The quarter reveals a company at odds with itself. Half-year growth of +35.6% year-on-year looks solid, but Q2 alone fell 12.6% — a 29.9% sequential drop that signals uneven commercialization, not broad-based momentum. Profit declined 46.7%, and this is operational, not a one-time charge. EBITDA margin fell 740 basis points to 22.9%, well below management's own 'normalized' target of ~25% (stated on the prior call). Management is building long-term (peptides facility live, Kakinada 134 acres), and those bets have merit. But the near-term story — how margins recover, when lumpiness ends, when growth re-accelerates — has gone opaque. And after missing the prior call's ~20% FY27-28 growth guidance, management now refuses to quantify the path forward.

EBITDA margin of 22.9% vs 30.4% a year earlier is a 740 basis-point miss. Management blames input-cost inflation, freight escalation, and uneven commercial shipment timing — all real. But the scale of the decline, and the fact that even the 'normalized' target (25%) is out of reach, raises a harder question: how much is cyclical, and how much reflects structural pressure in CDMO pricing as capacity adds globally? Net margin at 11.3% (down from 18.8%) is a level that should concern holders. Working capital cycle deteriorated to 104 days from 84 days (+20 days), signaling either inventory buildup or slower collections — a cash-flow headwind unresolved.

On the prior call (FY27 opening), management guided for ~20% FY27-28 growth and a 'normalized EBITDA margin of ~25%'. Q2 delivered -12.6% revenue growth and 22.9% EBITDA — both misses. When asked on this call for a fresh guidance range, management refused: 'It is difficult. I do not think we are precise enough to go into more clarity there. 2027 will grow and 2028 will grow, but we do not want to share numbers.' This is a red flag. After missing prior guidance, the unwillingness to re-quantify — even a range — damages credibility. The specialty (GDS) segment weakness was also unforecast; management blamed geopolitical disruption affecting customers' manufacturing, a headwind not pre-warned. Long-term bets (peptides facility live, Kakinada 134 acres, ₹1700 Cr capex over 3 years) are credible — but they buy time, not near-term clarity.

How the street is positioned: The stock trades at ₹19,700 as of 2026-11-06, down 18.68% from its all-time high of ₹24,225 but up 71.3% from its 52-week low of ₹11,500. Technicals are mixed: trading below the 50-day average (₹21,392) but above the 200-day (₹17,523); RSI of 43.6 is neutral. Volume is increasing, signaling renewed interest or capitulation. Institutional flows show slight net buying: FII at 21.08% (+0.62 percentage points QoQ), DII at 16.51% (+0.67pp), promoters steady at 32.62%. A bulk deal by HDFC Mutual Fund for 64,547 shares at ₹21,585 — above current price — is a vote of confidence, though modest in scale. No insider selling is flagged. The market appears to be pricing in: (a) near-term margin pressure and customer concentration risk, (b) long-term upside if infrastructure bets deliver, and (c) execution uncertainty on guidance. The 18.68% drawdown from ATH reflects a repricing of growth assumptions after the miss — appropriate, given the guidance retreat.